$GILD News

Ahead of Gilead (GILD) Q3 Earnings: Get Ready With Wall Street Estimates for Key Metrics

Gilead Sciences (GILD) Could Be 22% Overvalued Following Its Liver Meeting Update

The Lanier Law Firm Supports Attorney General Ken Paxton in Reaching $45 Million Settlement with Gilead in Unlawful Inducement Scheme

Gilead spends $1.28bn on PepStar’s potential Icotyde rival

Gilead to Acquire Investigational Oral IL-23R Inhibitor HCXT-2001, Strengthening Its Inflammation Pipeline in IBD

Gilead Sciences Agrees To Acquire Oral IL-23R Inhibitor Program From PepStar Therapeutics Under $1.275B Deal

Gilead Sciences (GILD) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release

Gilead to Present New Data on Treatment Response and Long-Term Management of Rare Liver Diseases at The Liver Meeting® 2026

Gilead Sciences (GILD) Stock Drops Despite Market Gains: Important Facts to Note

B of A Securities Maintains Buy on Gilead Sciences, Raises Price Target to $172

How Investors Are Reacting To Gilead Sciences (GILD) FDA Drug Approvals

All You Need to Know About Gilead (GILD) Rating Upgrade to Buy

Gilead Bolsters Inflammatory Bowel Disease Pipeline With Promising Mid-Stage Trial Success

Gilead to Present New Data Across HIV and Emerging Antiviral Research at IDWeek 2026

Gilead Announces Emvistegrast 200 Mg Met Primary Endpoint In Phase 2 Swift Dose-Ranging Study; Demonstrated Significant Differences Across Multiple Secondary Measures Of Disease Activity Based On Nominal P-Values; Plans To Initiate Phase 3 Emvistegrast Monotherapy Study In 2027

Gilead Sciences Is on an FDA Approval Hot Streak. Should You Buy the Stock Like There's No Tomorrow?

Stocktwits Biotech Dealmaker: Gilead, AstraZeneca And Roche Chase Pipeline Expansion Over Buyouts

Gilead Sciences (GILD) Rises Higher Than Market: Key Facts

Gilead Sciences to Release Third Quarter 2026 Financial Results on Thursday, October 29, 2026

Final Trade: AEM, IEV, BABA, GILD